Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2022-08-10 Transaction in Own Shar…
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第十次会议相关事项的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent director's opinion on a share repurchase (buyback) proposal presented at a board meeting. It discusses the legality, rationale, and impact of the share repurchase plan. There is no financial data or full report attached, nor is it an announcement of voting results or management changes. The content fits the category of a Transaction in Own Shares (POS) report, which covers company buyback activities. The document length is short and focused on the share repurchase plan's approval and opinion, consistent with POS filings.
2022-08-10 Chinese
回购股份方案公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding a share repurchase plan by Guangdong Yongshun Biopharmaceutical Co., Ltd. It includes specifics on the number of shares to be repurchased, pricing, purpose (mainly for equity incentives), funding sources, implementation period, and impact on shareholding structure. It also discusses financial condition analysis related to the repurchase and regulatory compliance. The document is not a financial report, earnings release, or management discussion but a formal announcement of a share buyback program. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares. The document length is 4327 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the correct classification is POS with high confidence.
2022-08-10 Chinese
第四届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 10th meeting of the 4th Board of Directors of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results, specifically about a share repurchase plan. This fits the category of Board/Management Information (MANG), as it concerns board meeting decisions and management actions. The document is not a full financial report, audit, or earnings release, nor is it a regulatory filing or announcement of a report publication. The length and content confirm it is a board meeting resolution announcement.
2022-08-10 Chinese
第四届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 9th meeting of the 4th Board of Directors of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on various proposals, including approval of the 2022 semi-annual report, special report on fundraising usage, investment in a wholly-owned subsidiary, and a loan pledge using patents. The document does not contain the actual semi-annual report or financial data but references where these reports can be found. It is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short and it is not the report itself but an announcement of board decisions.
2022-07-28 Chinese
第四届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on several agenda items, including approval of the 2022 semi-annual report, a special report on fundraising usage, an investment proposal, and a loan pledge proposal. The document references other filings where the full reports are disclosed, indicating this is a meeting resolution announcement rather than the reports themselves. The document is short (1523 characters) and primarily serves to announce the resolutions passed at the Supervisory Board meeting. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not contain the full financial reports or detailed data itself.
2022-07-28 Chinese
对外投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Guangdong Yongshun Biopharmaceutical Co., Ltd. regarding an external investment to establish a wholly-owned subsidiary. It details the investment overview, approval by the board, investment purpose, risks, and impact on the company. There is no financial data or report content, only an announcement of a corporate action related to investment. The document length is short (1538 characters), and it is clearly an announcement of a corporate investment decision rather than a financial report or detailed management discussion. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to company fundraising or capital structure changes through establishing a subsidiary.
2022-07-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.